Search | Clinical Trials Finder

Conditions: Schizophrenia
Interventions: Ziprasidone, Olanzapine, Placebo Comparator; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 40 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Opioid Use Disorder
Interventions: Olanzapine; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Richmond, Virginia

Conditions: Schizophrenia
Interventions: Intramuscular Olanzapine Depot, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 402 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 34
States / cities: National City, California • Orange, California • Rosemead, California + 31 more

Conditions: Schizophrenia
Interventions: LY2140023, aripiprazole, olanzapine, risperidone; Drug
Lead sponsor: Denovo Biopharma LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 11
States / cities: Escondido, California • Garden Grove, California • Washington D.C., District of Columbia + 8 more

Conditions: Major Depressive Disorder With Psychotic Features
Interventions: Olanzapine, Sertraline, placebo; Drug · Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 3
States / cities: Worcester, Massachusetts • New York, New York • Pittsburgh, Pennsylvania

Conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions: Dipyridamole, Olanzapine; Drug · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Insulin Resistance, Metabolic Syndrome X, Schizophrenia and Disorders With Psychotic Features, Mood Disorders, Psychotic Disorders
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 30 Years to 66 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Aripiprazole, Olanzapine, Paliperidone, Quetiapine, Risperidone; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Torrance, California • Kissimmee, Florida • Conshohocken, Pennsylvania

Conditions: Schizophrenia, Psychotic Disorders, Bipolar Disorder
Interventions: Sibutramine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 16
States / cities: El Centro, California • Jacksonville, Florida • Miami, Florida + 13 more

Conditions: Schizophrenia
Interventions: Olanzapine, Omega 3, Vitamin E+C; Drug
Lead sponsor: Augusta University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2005
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
Interventions: Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation, Paliperidone, LAI, Quetiapine, oral formulation, Risperidone, oral formulation, Risperidone, LAI; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 6
States / cities: Garden Grove, California • Kissimmee, Florida • Atlanta, Georgia + 3 more

Conditions: Apathy, Schizophrenia, Schizophrenia; Psychosis
Interventions: Lumateperone 42 mg, Risperidone 2 mg; Drug
Lead sponsor: Louisiana State University Health Sciences Center Shreveport; Other
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Shreveport, Louisiana

Conditions: Schizophrenia
Interventions: ASP4345, placebo, risperidone, quetiapine, olanzapine, ziprasidone, aripiprazole, brexpiprazole, paliperidone, lurasidone; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 27
States / cities: Cerritos, California • Garden Grove, California • Lemon Grove, California + 19 more

Conditions: Schizophrenia, Schizophreniform Disorders, Bipolar I Disorder
Interventions: ALKS 3831, Olanzapine; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 16 Years to 40 Years
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 25
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Garden Grove, California + 19 more

Conditions: Cancer-Associated Anorexia, Head and Neck Squamous Cell Carcinoma, Neck Squamous Cell Carcinoma of Unknown Primary
Interventions: Best Practice, Olanzapine, Questionnaire Administration; Other · Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Agitation in Adolescents and Young Adults With ASD
Interventions: INP105, Placebo; Combination Product
Lead sponsor: Impel Pharmaceuticals; Industry
Eligibility: 12 Years to 21 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Portland, Maine • Cincinnati, Ohio

Conditions: Schizophrenia
Interventions: Caregiver psycho-education and skills training, Caregiver support available at the study site, Paliperidone palmitate, Chlorpromazine, Droperidol, Fluphenazine, Haloperidol, Loxapine, Perphenazine, Pimozide, Prochlorperazine, Thiothixene, Thioridazine, Trifluoperazine, Aripiprazole, Asenapine, Clozapine, Iloperidone, Olanzapine, Paliperidone, Quetiapine, Risperidone, Ziprasidone; Other · Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 34
States / cities: Bullhead City, Arizona • Oceanside, California • Denver, Colorado + 31 more

Conditions: Schizophrenia
Interventions: Risperidone, Olanzapine; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 60 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Chemotherapy Induced Nausea and Vomiting
Interventions: Olanzapine, Aprepitant; Drug
Lead sponsor: Indiana University; Other
Eligibility: 4 Years to 21 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Bipolar I Disorder
Interventions: Injectable Risperidone (Consta) or oral antipsychotic; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 4
States / cities: Bridgeville, Pennsylvania • DuBois, Pennsylvania • McKeesport, Pennsylvania + 1 more

Conditions: Schizophrenia
Interventions: SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole); Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Dayton, Ohio + 1 more

Conditions: Schizophrenia
Interventions: olanzapine, atomoxetine, placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 20
States / cities: Cerritos, California • Chula Vista, California • Garden Grove, California + 15 more

Conditions: Autism
Interventions: Olanzapine; Drug
Lead sponsor: Drexel University; Other
Eligibility: 3 Years to 12 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Alzheimer's Disease
Interventions: Olanzapine, Quetiapine, Risperidone, Citalopram; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 34
States / cities: Tuscaloosa, Alabama • Irvine, California • Los Angeles, California + 29 more

Search by objective public record fields.

Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia

Olanzapine in OUD Patients

Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia

A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients

Study of Pharmacotherapy of Psychotic Depression

Clinical Trial of Dipyridamole in Schizophrenia

Side Effects of Antipsychotic Medications

A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry

The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder

Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids

Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants

Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.

A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder

Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial

INP105 Proof-of-concept Study for the Acute Treatment of Agitation in Adolescents and Young Adults With ASD

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

Atypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRI

Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy

Risperdal Consta for Bipolar Disorder

A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia

A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia

Long-Term Olanzapine Treatment in Children With Autism

CATIE-Alzheimer's Disease Trial